Leerink Adjusts Price Target on DexCom to $151 From $161
DexCom Analyst Ratings
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $120
Morgan Stanley Cuts Price Target on DexCom to $120 From $132, Keeps Equalweight Rating
DexCom Analyst Ratings
Stifel Maintains Buy on DexCom, Lowers Price Target to $132
Stifel Nicolaus Remains a Buy on Dexcom (DXCM)
Dexcom's Strategic Expansion and Product Launches Merit a Buy Rating
DexCom Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
Morgan Stanley Adjusts DexCom's Price Target to $132 From $122
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From Stifel Nicolaus
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
Dexcom's Strong Q1 Performance and Upbeat 2024 Outlook Justify Buy Rating
RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)
DexCom Analyst Ratings
UBS Raises DexCom's Price Target to $163 From $153, Maintains Buy Rating